Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
08
2018
revised:
09
12
2018
accepted:
31
12
2018
entrez:
26
3
2019
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
Ruyan Neixiao Cream (RYNXC), a patented Chinese herbal formula, was reported to have the effect of treating mammary precancerous disease. In this study, we predicted the potential targets, pathways, and diseases of the ingredients contained in each herbal of RYNXC and constructed an ingredients-targets-diseases network. Then, we analyzed molecular mechanisms of this Chinese herbal formula by MCF-10AT cells and model rats of breast precancerous lesions. BATMAN-TCM prediction showed that ESR1, PGR, PTGS2, EGFR, and Src were mRNA targets of RYNXC. Our results suggested that RYNXC transdermal fluid downregulated ESR1, PGR, PTGS2, EGFR, and Src expression at gene and protein level in MCF-10AT cells. In the rat breast precancerous lesions model, high and low dose RYNXC could also significantly reduce genes and proteins expression of ESR1, PGR, PTGS2, EGFR, and Src. Taken together these data indicate that RYNXC targets multiple molecules responsible for breast precancerous lesion and is an effective Chinese herbal formula. So RYNXC may be a promising external drug for breast precancerous lesions.
Identifiants
pubmed: 30906412
doi: 10.1155/2019/2795010
pmc: PMC6398062
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2795010Références
Adv Cancer Res. 2000;77:25-79
pubmed: 10549355
Cell Death Differ. 2000 Aug;7(8):685-96
pubmed: 10918442
Breast Cancer Res. 2000;2(3):170-5
pubmed: 11250706
Breast Cancer Res. 2000;2(3):211-6
pubmed: 11250712
Breast J. 1999 Mar;5(2):122-129
pubmed: 11348271
Science. 1976 Jan 23;191(4224):295-7
pubmed: 1246614
J Clin Oncol. 2003 Jan 1;21(1):41-5
pubmed: 12506168
Cancer. 2003 Jun 15;97(12):2978-87
pubmed: 12784332
Endocr Rev. 1992 Feb;13(1):3-17
pubmed: 1313356
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6
pubmed: 14688410
Biochim Biophys Acta. 2006 Apr;1765(2):235-55
pubmed: 16410040
Oncology. 2006;71(1-2):1-9
pubmed: 17344666
Breast Cancer. 2007;14(2):194-9
pubmed: 17485906
Breast Cancer Res Treat. 2008 May;109(2):189-98
pubmed: 17624587
Clin Pharmacol Ther. 2008 Jan;83(1):26-36
pubmed: 18091763
Oncogene. 2009 May 21;28(20):2074-86
pubmed: 19377510
PLoS One. 2009 May 20;4(5):e5624
pubmed: 19462000
J Surg Res. 2011 Jun 1;168(1):e39-49
pubmed: 20462604
Cell. 2010 Jun 25;141(7):1117-34
pubmed: 20602996
Br J Cancer. 2010 Sep 7;103(6):899-909
pubmed: 20717116
Semin Cell Dev Biol. 2010 Dec;21(9):951-60
pubmed: 20813200
Cancer Chemother Pharmacol. 2011 Nov;68(5):1315-23
pubmed: 21461888
Cancer Treat Rev. 2013 Feb;39(1):44-50
pubmed: 22541668
Evid Based Complement Alternat Med. 2013;2013:376123
pubmed: 23864887
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Lancet Oncol. 2015 Jan;16(1):67-75
pubmed: 25497694
Cancer Cell. 2015 Mar 9;27(3):354-69
pubmed: 25759021
Int J Mol Sci. 2015 Apr 10;16(4):8102-9
pubmed: 25867480
Nature. 2015 Jul 16;523(7560):313-7
pubmed: 26153859
J Natl Compr Canc Netw. 2015 Aug;13(8):e56-64
pubmed: 26285250
JAMA Oncol. 2015 Oct;1(7):888-96
pubmed: 26291673
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Sci Rep. 2016 Feb 16;6:21146
pubmed: 26879404
Cancer Gene Ther. 2017 Sep;24(9):361-366
pubmed: 28752861
Evid Based Complement Alternat Med. 2017;2017:6235027
pubmed: 28811827
Oncotarget. 2017 May 5;8(34):56296-56310
pubmed: 28915591
Sci Rep. 2017 Oct 10;7(1):12920
pubmed: 29018241
J Chem Inf Model. 2018 Mar 26;58(3):550-555
pubmed: 29420025
Breast Cancer Res Treat. 1995 Jul;35(1):133-44
pubmed: 7612899
Mod Pathol. 1998 Feb;11(2):120-8
pubmed: 9504682
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
pubmed: 9747868